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https://doi.org/10.1016/j.idh.2017.10
2468-0451/ª 2017 The Authors. Publis
open access article under the CC BY-NAbstract Introduction: Increasingly, over the past decade, there has been a global shift in
healthcare away from fixed “fee for service” payment mechanisms towards value-based reim-
bursement models rewarding safety and quality patient outcomes. Curbing the burgeoning
costs of healthcare while incentivising higher quality and safer patient care are key drivers
of this approach. At face value, this is clearly a worthwhile endeavour. However, there is a
lack of conclusive evidence to support the effectiveness of such schemes where they have
been introduced internationally. For this reason, Australia has largely been an observer of
the shift in payment modalities that are occurring in other countries such as the United States
and the United Kingdom.
Method: This paper presents an overview of current Australian practice in pricing for safety
and quality in Healthcare. Recommendations are provided to help infection control profes-
sionals prepare for the upcoming introduction of funding reforms aimed at reducing complica-
tions acquired in Australian public hospitals.
Conclusion: The implications for infection control professionals are wide-ranging. This will be
a period of significant adjustment for the public health system in Australia.
ª 2017 The Authors. Published by Elsevier B.V. on behalf of Australasian College for Infection
Prevention and Control. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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50 B. Magid et al. Australia has largely been an observer of this transition due to a lack of supporting evidence
globally.
 Major changes in Australian public hospitals will see penalties for hospital acquired com-
plications from mid-2018.
 The infection control program will experience increased prominence and scrutiny due to
these changes.
 Infection control professionals are well positioned to lead the conversation with hospital
management around evidenced-based safety and quality initiatives.Introduction
Acute healthcare in Australia is currently provided through
a mix of public and private hospitals. Approximately two-
thirds of healthcare funding comes from government, with
the remaining third coming from private health insurance,
individuals and other non-government sources [1]. Health-
care costs are significant, reaching 10% of gross domestic
product (GDP) for the first time in 2014e15 [1]. The largest
component of healthcare spending is attributable to hos-
pitals [2].
The proposed funding changes impacting Australian public
hospitals will come into effect by 1 July 2018. However, the
concept of pricing for safety and quality in healthcare has
been under investigation in Australia since 2012, primarily by
the Independent Hospital Pricing Authority (IHPA) in collab-
oration with the Australian Commission on Safety and Quality
in Health Care (ACSQHC). These groups conducted a
comprehensive literature review of the international evi-
dence in 2013 [3], and a literature update in 2015 [4]. They
also developed a list of high-priority hospital acquired com-
plications (HACs) in a clinician drivenprocess, and trialled this
in both public and private hospitals [5]. In 2016, IHPA released
proposals for funding changes incorporating the list of HACs to
encourage safety andquality in healthcare [6]. The aimof this
paper is to provide an overview of the funding changes and to
discuss the practical implications for Australian infection
control professionals (ICPs).
Lessons from the private sector
Before considering the complex public system funding
changes and their implications for Australian infection
control professionals, it is worthwhile considering progress
of similar change in the private sector. From mid-2014,
Australia’s largest insurer, Medibank Private, began to
include quality based terms in their contracts with private
hospitals [7]. As of December 2015, Medibank had amended
their contracts to include these terms with approximately
70% of Australia’s major private hospitals [8].
In practice, the contractual changes meant that if a
privately insured patient experienced a specific HAC, such
as a pressure injury or healthcare associated infection
(HAI), the insurer would only pay the hospital for the pri-
mary condition, with the private hospital assuming financial
responsibility for any additional costs related to therespective HAC. In addition, if a privately insured patient
was re-admitted to hospital within a set period due to post
discharge complications related to a HAC, the private
hospital would assume responsibility for the cost of this
readmission. The HACs identified by Medibank were broadly
categorised as follows:
❖ Sentinel events
❖ Pressure injuries
❖ Falls resulting in fracture and intracranial injury
❖ Healthcare associated infections (HAI)
❖ Surgical complications
❖ Venous thromboembolism (VTE)
Medibank has received widespread public criticism for
this approach to “pricing” for patient safety and quality
outcomes. In contrast, they received support for this
approach from other insurers including the British United
Provident Association (BUPA) and nib health funds (nib). Aside
from the public commentary, it is useful to look at the impact
these changes have had on hospital acquired complication
rates.
Examination of the results provided by Medibank, show
some positive trends. Two unspecified major private hos-
pital groups with the highest initial HAC rates showed re-
ductions in the 12 months post contract renewal [7]. Their
HAC rates reduced from 25 to 16 per 1000 acute overnight
separations in the post contract period [7]. These results
compare favourably with the average HAC rates of 29 per
1000 acute admitted episodes recorded in the public sector
[6]. However, improvements have not been consistent e
two other private hospital groups showed no change in re-
ported HAC rates post contract changes. Conclusions
cannot yet be drawn from these results, similar to the
experience with more comprehensive studies conducted
internationally [3,4,9,10].
It is important to note that Medibank has subsequently
articulated the importance of incentives, in combination
with disincentives, to drive positive outcomes and they
have adjusted their most recent contracts accordingly [11].
Impact on the public health system
In the US, hospital funding changes targeting quality were
first introduced by the Government in 2006. In contrast, in
Australia, insurers of the private sector have initially driven
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the Australian Federal Health Minister instructed the IHPA
to proceed with developing funding options to improve
safety and quality in Australian public hospitals. The di-
rection to IHPA included instructions to target sentinel
events, a set of preventable hospital acquired complica-
tions (HACs), and avoidable readmissions for an agreed set
of conditions [12] (Table 1). Pricing for sentinel events
commenced on 1 July 2017 [5]. Pricing for HACs will
commence from 1 July 2018 with a year of shadow pricing
from 1 July 2017 [5]. The specific details of the shadow
pricing year are not yet available, but during this time IHPA
will assess the impact of the HACs pricing model and report
the findings to the Council of Australian Governments
(COAG) for commencement of funding changes from 1 July
2018. The introduction of a funding approach to combat
avoidable hospital readmissions has been delayed pending
further work around defining a list of clinical conditions
deemed to be “avoidable” readmissions [5].
Separate to the federal changes to funding, some
Australian states have independently introduced various
state-specific financial incentive/disincentive/penalty
schemes over the past several years. For example,
Queensland Health has applied penalties for every reported
case of healthcare acquired bacteraemia ($10,000 AUD), as
well as stage 3 pressure injuries ($30,000 AUD) and stage 4
pressure injuries ($50,000 AUD) [3,13]. The key difference
in the new proposed federal scheme is that it will apply to
all public hospitals throughout Australia and it will have
significantly wider scope than any previous state based
schemes [6]. The crux of the federal scheme is that it will
reduce payments to public hospitals for episodes of care
that incur one or more preventable hospital acquired
complication. Significantly, unlike recent moves by the
private sector, there will be no positive adjustments to
reward quality care paired with these financial disincen-
tives [5]. Two critical unknowns at this stage are the
magnitude of the financial penalties to be applied to hos-
pitals under the federal scheme and the distribution of
proceeds from these penalties. Regarding the distribution
of proceeds, there is a strong argument that resources need
to be made available for quality improvement efforts at the
hospital level in order to maximise improvements in patient
outcomes [14].
It is also important to consider the complexities associ-
ated with the concept of preventability in discussingTable 1 Definitions [5].
Sentinel events: Sentinel events are a subset of
adverse events that result in death or
serious harm to a patient and occur
due to systems and process
deficiencies.
Hospital acquired
complications
(HACs):
HACs are complications which occur
during a hospital stay and for which
clinical risk mitigation strategies may
reduce (but not necessarily
eliminate) the risk of that
complication occurring.hospital acquired complications (HACs). There are a
multitude of factors which influence the extent to which an
acquired complication is preventable and these factors
change over time [15]. There is also significant variation in
preventability between facilities due to the varying levels
of access to relevant technology [15]. If information about
funding adjustments is publicly reported, inter-facility
variability must be clarified to avoid unwarranted reputa-
tional damage to hospitals. Moreover, given the fluid nature
of the concept of preventability, ICPs should contribute to
the ongoing review and modification of the list of target
complications to ensure its continued appropriateness. The
Australian Commission on Safety and Quality in Healthcare
(ACSQH) has been tasked with leading the effort of
continual refinement of the list [5].
Implementation challenges
The funding adjustments to hospitals will be made on the
basis of what is known as the condition onset flag (COF) [5].
The COF is a marker entered into the patient’s record by
hospital coding staff to identify if a HAC was in fact hospital
acquired, or whether it was present on admission. This is
the only practicable way to implement such a wide ranging
policy of penalties for HACs in public hospitals. However, it
presents a challenge, as hospitals with poor quality COF
data could be exempt from financial penalties which cre-
ates incentives for under-reporting. As such, IHPA proposed
that hospitals with poor quality COF data would be penal-
ised at the same rate as hospitals with high quality COF
data, but high HAC rates [6]. The authors strongly support
this approach. However, IHPA has subsequently decided to
replace this proposal with a revised program of audit to be
implemented at the state and territory level. Another
implementation problem with COF reporting is that it does
not capture conditions which were present on admission
but worsened during the patient’s stay in hospital.
A final challenge in implementing financial penalties
associated with COF data, is that HAC rates calculated from
administrative coding data typically differ from HAC sur-
veillance conducted throughout the hospital [16,17]. This is
particularly relevant for ICPs who are charged with con-
ducting HAI surveillance throughout the hospital. It is likely
that differences will emerge between the HAI rates from
ICP surveillance and the COF determined rates. These dif-
ferences can potentially be mitigated through strategies
aimed at educating HCPs around medical record docu-
mentation requirements. These requirements are essential
for clinical coding staff to accurately code COF data and
ICPs could drive education for HCPs around medical record
documentation requirements. This will minimise cases
where the COF determined rates vary from the ICP deter-
mined rates.
Unintended consequences
The unintended consequences of such a funding scheme are
significant and commonly include; inclination for organisa-
tions to select the easiest patients, to underreport target
conditions and to reduce scrutiny of non-target conditions
[3,18]. To guard against hospitals selecting the easiest
52 B. Magid et al.patients, IHPA has commissioned expert advice on risk
adjustment to ensure that hospitals treating high risk pa-
tients are compensated accordingly [5]. Regarding vari-
ability of reporting, IHPA will provide direction to states
and territories to support programs to audit medical re-
cords and coding as referenced above [5]. Quantifying the
implications on non-target conditions is uncertain [18].
However, robust reporting should identify deteriorations in
non-target areas and appropriate feedback from ICPs could
potentially mitigate this situation. Systemic deterioration
in certain HAIs which are non-target conditions should feed
into the Commission led review process of the target
complications list outlined above. Regardless, the impacts
of the funding changes will need to be closely monitored to
ensure that unintended consequences are minimised and
the goal of improving patient outcomes is realised.
Impact on the Australian infection control
professional
The implications for the modern Australian infection con-
trol professional are potentially wide ranging. The infec-
tion control program will experience both increased
prominence and scrutiny as hospital administrators and
management look to infection control professionals (ICPs)
for ways to reduce the burden of HAIs. The infection
control professional has extensive experience in preven-
tion, control, data collection, analysis and reporting.
Hospital management may expect and facilitate increased
collaboration between ICPs and various stakeholders
working within the hospital to combat pressure injuries,
VTEs, and other target conditions.
Expanding the scope of work is a challenging suggestion
for an infection control department already dealing with
significant resource constraints. For this reason, ICPs should
take this opportunity to put forth a substantial business
case and argument for additional and varied resources
needed to achieve HAC reductions. Increased resources and
additional headcount will be critical to making meaningful
improvements in the fight against hospital acquired com-
plications. Not only will additional ICPs be required, but
additional HCPs with expertise in other areas of HAC
reduction will be needed.
Conclusion
With the aid of additional resources and varied expertise,
the infection control departments of Australia are well
positioned to lead hospital acquired complication re-
ductions. Australian ICPs have well established networks
within their hospitals. They are well versed in disseminating
evidence-based best practice and locally tailored solutions
and they are masters of influence despite often lacking
direct authority. This skillset will be invaluable in imple-
menting quality improvement projects and reducing rates
of all HACs.
Rather than dreading the winter that is coming, this is an
exciting time for Australian ICPs to lead the conversation
with hospital management around evidenced-based safety
and quality initiatives. Moreover, these policy changespresent a unique opportunity to transform the traditional
infection control departments around the country into
hospital acquired complication reduction departments
which will benefit from increased strategic focus and
funding.
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